Medications for Nonsmall Cell Lung Carcinoma

24 results

  • Bizengri (zenocutuzumab)

    (Zenocutuzumab)
    Merus US, Inc.
    Usage: BIZENGRI is indicated for adults with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma that possess a neuregulin 1 (NRG1) gene fusion and have progressed after prior systemic therapy. Approval is based on overall response rate and duration of response.

  • Docetaxel (docetaxel)

    (Docetaxel)
    Dr. Reddy's Laboratories Inc.
    Usage: Docetaxel injection is indicated for treating locally advanced or metastatic breast, non-small cell lung, prostate, gastric adenocarcinoma, and head and neck cancers. It is used alone or in combination with other drugs, primarily after prior chemotherapy failure or for adjuvant treatment in certain patients.

  • Docetaxel (docetaxel)

    (Docetaxel)
    Mylan Institutional LLC
    Usage: Docetaxel Injection is indicated for treating locally advanced or metastatic breast cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer, advanced gastric adenocarcinoma, and locally advanced head and neck cancer, often in combination with other chemotherapy agents, after prior treatments have failed.

  • Docetaxel (docetaxel)

    (Docetaxel)
    Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
    Usage: Docetaxel Injection is indicated for treating locally advanced or metastatic breast cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer, advanced gastric adenocarcinoma, and locally advanced squamous cell carcinoma of the head and neck, often in combination with other chemotherapeutic agents.

  • Docetaxel (docetaxel)

    (Docetaxel)
    Gland Pharma Limited
    Usage: Docetaxel Injection is indicated for treating locally advanced or metastatic breast cancer after prior chemotherapy, non-small cell lung cancer post platinum-based therapy, metastatic castration-resistant prostate cancer with prednisone, advanced gastric adenocarcinoma, and induction therapy for locally advanced squamous cell carcinoma of the head and neck.

  • Docetaxel (docetaxel)

    (Docetaxel)
    Eugia US LLC
    Usage: Docetaxel injection is indicated for treating locally advanced or metastatic breast, non-small cell lung, prostate, gastric, and head and neck cancers, often in combination with other chemotherapeutic agents. It is used after prior chemotherapy failures or for patients who have not previously received treatment for certain conditions.

  • Docetaxel anhydrous (docetaxel anhydrous)

    (Docetaxel anhydrous)
    Meitheal Pharmaceuticals Inc
    Usage: Docetaxel Injection is indicated for locally advanced or metastatic breast cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer, advanced gastric adenocarcinoma, and head and neck cancer. It is used as a single agent or in combination with other chemotherapeutic agents based on specific patient conditions.

  • Erlotinib (erlotinib)

    (ERLOTINIB)
    Camber Pharmaceuticals, Inc.
    Usage: Erlotinib tablets are indicated for treating metastatic non-small cell lung cancer (NSCLC) in patients with specific EGFR mutations and for first-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer when combined with gemcitabine. Not recommended for NSCLC with other EGFR mutations or with platinum-based chemotherapy.

  • Erlotinib (erlotinib)

    (Erlotinib)
    Areva Pharmaceuticals
    Usage: Erlotinib Tablets are indicated for treating metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations and for first-line treatment of locally advanced or metastatic pancreatic cancer when combined with gemcitabine. Efficacy has not been established for other EGFR mutations or with platinum-based chemotherapy.

  • Gefitinib (gefitinib)

    (Gefitinib)
    Apotex Corp.
    Usage: Gefitinib tablets are indicated as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) in patients with tumors that have EGFR exon 19 deletions or exon 21 (L858R) mutations. Safety and efficacy in other EGFR mutations have not been established.